Pharma CEOs lean Republican with 2018 election donations. So who's the sole Democrat?

CEOs for Merck, Eli Lilly, Pfizer, Allergan and Amgen gifted to mostly Republican causes this election season, while one industry helmsman bucked the trend. (Pixabay)

With Democrats trying to wrest control of the government from the Republicans, all eyes are on some hotly contested congressional and gubernatorial races—and some biopharma CEOs aren't just watching. They're putting money behind their favored candidates and causes.

Among a group of top partisan spenders tracked by MarketWatch, biopharma CEOs gave mostly to Republicans—and in one case, only singled out GOP candidates. That would be Allergan CEO Brent Saunders, who handed out $100,100, all to Republicans.

Only one pharma CEO featured in the group leaned Democratic, and he went blue all the way. Regeneron’s Leonard Schleifer gave $120,000 this election cycle, entirely to Democrats.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The handful of other biopharma donors spotlighted in the report each gave at least a small amount to Democrats, though they overwhelmingly supported the GOP. Mark Alles, Celgene’s CEO and successor to New Jersey senate candidate Bob Hugin, gave $188,600 to mostly Republican causes, while Merck & Co.’s Ken Frazier gave $188,500, Pfizer’s Ian Read donated $171,200 and Eli Lilly’s David Ricks shelled out $112,800. Amgen’s Robert Bradway, meanwhile, gave $235,800, also to mostly Republican causes.

RELATED: Right after Trump blamed high drug prices on campaign cash, drugmakers gave more

The contributions are from individual CEOs, not the companies they run. But they come during a tense time for drugmakers as drug pricing continues to generate attention nationwide. This weekend, the New York Times reported that the industry is preparing for a potential worst-case scenario of Democrats and the Trump administration teaming up to rein in drug prices after the election.

After his election, President Donald Trump has said the industry is “getting away with murder” and his administration has taken several steps to try to fight high prices. In May, the administration released its drug pricing blueprint, calling for more competition and negotiation in the drug markets, plus incentives to lower list prices and lower out of pocket costs. HHS is also pushing ahead with a requirement for drug prices in TV ads.

RELATED: PhRMA lobby spend grows to $15.5M in the first half of 2018

Meanwhile, PhRMA, the industry’s top lobbying organization, upped its lobbying spend by 30% in 2017 to $25.43 million, aiming to sway lawmakers toward the industry's message. The organization again boosted its lobbying spend in the first half of this year to $15.5 million, an 11% increase over the same period in 2017.

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.